HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council
A Multicenter, Non-Interventional, Retrospective Study Aims to Estimate the Prevalence and Describe the Clinical Manifestations of HER2-Low Breast Cancer Reported in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2- Negative From Patient Medical Records in The Gulf Council Cooperation Region
Sponsor: AstraZeneca
A observational or N/A phase clinical study on Breast Cancer and Breast Carcinoma, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 12 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Nov 2025 — Present [monthly]
Completed
-
Oct 2025 — Nov 2025 [monthly]
Completed
-
Sep 2025 — Oct 2025 [monthly]
Completed
-
Dec 2024 — Sep 2025 [monthly]
Completed
Status: Recruiting → Completed
-
Oct 2024 — Dec 2024 [monthly]
Recruiting
▶ Show 7 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Recruiting
-
May 2024 — Jun 2024 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2024 — May 2024 [monthly]
Not Yet Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .